Damien Picard

Jan 10, 2025 | cell.com | Michael DiDonato |David Jones |Damien Picard |Ulrike Sommer |Eric Peters |Shelly L. Meeusen | +10 more

ResultsFor an IL-10 molecule to be effective in the treatment of inflammatory disease, a bioactive protein with an anti-inflammatory profile and an extended half-life is needed. To improve the half-life of IL-10, several standard protein engineering approaches exist, notably PEGylation and Fc fusion.

Feb 2, 2024 | ascpt.onlinelibrary.wiley.com | Christian Loesche |Damien Picard |Benjamin Van Hoorick |Imelda Schuhmann

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Leukotriene A4 Hydrolase (LTA4H) inhibitors have been investigated by the pharmaceutical industry for the treatment of neutrophil-driven inflammatory diseases. To date, no LTA4H inhibitors have reached the market, yet. WHAT QUESTION DID THIS STUDY ADDRESS? This study investigated the human pharmacokinetic (PK) to pharmacodynamic (PD) relationship and clinical safety of the potent and highly selective LTA4H inhibitor LYS006.